17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
15 apr - 
Glaxosmithkline får godkendt Victoza-konkurrent i USA -..
15 apr - 
Glaxosmithkline får godkendt Victoza-konkurrent i USA
15 apr - 
Novo: Tyske myndigheder vil ikke give Novoeight prisfor..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14 apr
NOVO-B
Du læser forkert, det han mener er, at han har for 400 kr Vestas, i 2014
3
14 apr
NOVO-B
Dine b&O er der ellers faldet pænt mgete i pæn lang tid...   Synd hverken du eller mikkel var mand n..
2
14 apr
NOVO-B
GOODWRENCH SIGER VETAS KURS 400 2014. Og så hader folk mig? Hvor pokker er din fornuft Good.
2
14 apr
NOVO-B
Goodwrench fokuser nu heller på hvad du selv kan gøre. Du kan sælge i aftenhandel selvom du nu igen ..
2
15 apr
NOVO-B
Lyt for Guds skyld kun til goodwrench hvis i vil have et godt grin..lader som om han er meget rutine..
1
15 apr
NOVO-B
Fedt for dig at du er sluppet ud med skindet på næsen med dine 6000 fantasi aktier som du også havde..
1
14 apr
NOVO-B
Det kommer ikke til at gå lang tid inden vi får godkendt  Tresiba 
1
14 apr
NOVO-B
Ja det har du. Skal også nok huske at give dig kredit hvis det sker. Bare synd at du ødelægger dit o..
1
14 apr
NOVO-B
Folk bliver federe og federe og flere og flere får sukkersyge. Total uafhængig af konjukturer, krige..
1
11 apr
NOVO-B
Lad den ramme 200 igen :-)
1

Fondsbørsmeddelelser

Danske/dir: Har indskærpet reglerne for vores handlere

16-04-2014 15:01:39
I lyset af den bøde, Danske Bank har fået for brud på børsens regler, har banken indskærpet handelsreglerne for sine mange handlere. Det fortæller Henrik Voetma..

Danske Bank får bøde på 410.000 kr. af børsen - NY

16-04-2014 13:11:16
Danske Bank har fået en bøde på 500.000 skr., eller 410.500 kr., af selskabet bag fondsbørsen i København, Nasdaq OMX.Bøden er givet, fordi banken angiveligt ha..

Aktier/middag: Nervøse smil præger fortsat markedet

16-04-2014 11:32:27
Investorerne ser ud til at ville fylde aktiedepoterne op, før kursen sættes mod røget laks, snaps og påskeferie. I hvert fald er de danske aktier i glimrende fo..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Farvel til fire dages fald
2
Topotarget fusionerer med fransk biotekselskab
3
Ny boligboble truer Danmark - avis
4
Topotarget/fmd: Fusionen spreder risikoen
5
Danske Bank får bøde på 410.000 kr. af børsen - NY

Relaterede aktiekurser

Novo-Nordisk A/S 43,98 2,6% Stigning i aktiekurs
Novo Nordisk B A/S 235,60 0,0% Aktiekurs uændret
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. april 2014 05:50:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140324.1 - EUROWEB6 - 2014-04-17 05:50:59 - 2014-04-17 05:50:59 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x